Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan

Neuropeptides

Volumn 32, Issue 3, 1998, Pages 275-280

  Raghavendra, V ^a   Chopra, K ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; APOMORPHINE; DOPAMINE; LOSARTAN; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PERPHENAZINE; RENIN;

ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; LOCOMOTION; MALE; MODULATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STEREOTYPY;

EID: 0031833474     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(98)90048-8     Document Type: Article

References (40)

1. Bunneman B, Fuxe K, Ganten D. The renin-angiotensin system in the brain: an up date 1993. Regul Pept 1993; 46: 487-509.
2. Lipsoldt A, Paul M, Fuxe K, Ganten D. The brain renin-angiotensin system: molecular mechanisms of cell to cell interactions. Clin Exp Hypertens 1995; 17: 251-266.
3. Banks RJA, Dourish C T. The angiotensin receptor antagonists Dup 753 and WL 19 block apomorphine induced stereotypy in the rat. Br J Pharmacol 1991; 104: 63.
4. Lind R W, Swanson L W, Ganten D. Organisation of angiotensin II immunoreactive cells and fibres in the rat CNS. Neuroendocrinology 1985; 40: 2-24.
5. Muratani H, Teruya H, Sesoka S, Takishita S, Fukiyama K. Brain angiotensin and circulatory control. Clin Exp Pharmacol Physiol 1996; 23: 458-464.
6. Wright J W, Harding J W. Brain angiotensin receptor subtypes in the control of physiological and behavioral response. Neurosci Biobehav Rev 1994; 18: 21-53.
7. Jenkins T A, Allen A M, Chai S Y, Mendelsohn FAO. Interactions of angiotensin II with central catecholamines. Clin Exp Hypertens 1995; 17: 267-280.
8. 1 receptor in vitro and in vivo. Br J Pharmacol 1996; 118: 414-420.
9. Dwoskin L P, Jewell A L, Cassis L A. DuP 753, a non peptide angiotensin II-1 receptor antagonist, alters dopaminergic function in the rat striatum. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 153-159.
10. Mendelsohn F A O, Jenkins T A, Berkovic S F. Effects of angiotensin-II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res 1993; 613: 221-229.
11. Kaliwas P W, Nemeroff C B, eds. The mesocorticolimbic dopamine system. Ann NY Acad Sci 1988; 537: xi-xii.
12. Li Z, Bains J S, Ferguson A V. Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull 1993; 30: 33-39.
13. Song K, Zhuo J, Mendelsohn F A O. Access of peripherally administered DuP 753 to rat brain angiotensin II receptors. Br J Pharmacol 1991; 104: 771-772.
14. Ahmad S. Losartan and reversible psychosis. Cardiology 1996; 87: 569-570.
15. Kulkarni S K. Handbook of Experimental Pharmacology, 2nd edn. New Delhi: Vallabh Prakashan, 1993: 61-63.
16. Kulkarni S K, Sharma A. Reversal of diazepam withdrawal induced hyperactivity in mice by BR 16-A (Mentat), a herbal preparation. Ind J Exp Biol 1994; 32: 886-888.
17. Costall B, Naylor R J. On the mode of action of apomorphine. Eur J Pharmacol 1973; 21: 350-361.
18. 2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology 1992; 109: 477-483.
19. Morpurgo C. Effect of anti-parkinsonian drugs on a pheriothiazine-induced catatonia reaction. Arch Int Pharmacodyn Ther 1962; 137: 84-90.
20. White N M. Control of sensory motor functions by dopaminergic nigro striatal neurons: influence on eating and drinking. Neurosci Biobehav Rev 1986; 10: 15-36.
21. Goa K L, Wagstaff A J. Losartan potassium. Drugs 1996; 51: 820-845.
22. Creese I, Burt D R, Snyder S H. Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. Science 1976; 192: 481-483.
23. Hornykiewicz O. Dopamine in the basal ganglia. Br Med Bull 1973; 29: 172-178.
24. Moal M L. Mesocortico limbic dopaminergic neurons, functional and regulatory roles. In: Bloom F E, Kupfer F E, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 283-294.
25. Chai S Y, McKenzie J S, Mckinly M J, Mendelsohn F A O. Angiotensin converting enzyme in human basal forebrain and midbrain visualized by in vitro autoradiography. J Comp Neurol 1990; 291: 179-194.
26. Chai S Y, Mendelsohn F A O, Paxinos G. Angiotensin converting enzyme in rat brain visualised by quantitative in vitro autoradiography. Neuroscience 1987; 20: 615-627
27. Lynch K R, Howelu-Johnson C L, Guyenet P G. Localization of brain angiotensinogen mRNA by hybridization histochemistry. Mol Brain Res 1987; 2: 149-158.
28. Allen A M, MacGregor D P, Chai S Y. Angiotensin II receptor binding associated with nigro-striatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992; 32: 339-344.
29. Wright J W, Harding J W. Regulatory role of brain angiotensin in the control of physiological and behavioral responses. Brain Res Rev 1992; 17: 227-262.
30. Phillips M I. Functions of angiotensin in the central nervous system. Annu Rev Physiol 1987; 49: 413-435.
31. Braszko J J, Wisniewski K, Kupryszewski G, Witczuk B. Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs cognitive behaviour. Behav Brain Res 1987; 25: 195-203.
32. Georgiev V, Gyorgy L, Getova D, Markovska V. Some central effects of angiotensin-II. Interaction with dopaminergic transmission. Bulg Acad Sci 1985; 11: 19-26.
33. Georgiev V. Involvement of transmitter mechanisms in the behavioral effects of angiotensin II. Pol J Pharmacol Pharm 1990; 42: 553-562.
34. Jenkins T A, Chai S Y, Howells D W, Mendelsohn F A O. Intrastriatal ang II induces turning in 6-hydroxy dopamine lesioned rats. Brain Res 1995; 691: 213-216.
35. Georgiev V. Angiotensin II modulation of behavior: implication of transmitter mechanisms. Neuropeptides 1993; 24: 223-230.
36. Georgiev V, Getova D, Opitz M. Mechanisms of the angiotensin II effects on the exploratory behavior of rats in open field. Interaction with saralasin and catecholaminergic drugs. Methods Find Exp Clin Pharmacol 1987; 9: 297-301.
37. Georgiev V, Kabourova T. Behavioral effects of angiotensin II in the mouse following MPTP administration. Gen Pharmacol 1991; 22: 625-630.
38. Georgiev V, Tanaka M, Tsuda A et al. Effects of angiotensin II on regional brain noradrenaline metabolism in nonstressed and stressed rats. Kurume Med J 1992; 39: 235-244.
39. Ouagazzal A, Nieoullon A, Amalric M. Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum. Eur J Pharmacol 1994; 251: 229-236.
40. 1 receptors in the mouse nucleus accumbens by chronic haloperidol treatment. Brain Res 1997; 748: 137-142.